Suchismita Daw

Suchismita Daw, PhD, is a healthcare analyst at Guidepoint since October 2024, focusing on monitoring public and private healthcare companies in Europe, tracking industry trends, and generating actionable insights for clients. Prior experience includes roles as Area Medical Advisor at Pfizer, where Suchismita launched a selective JAK1 inhibitor for Atopic Dermatitis and worked with various medications in specialized areas such as rare diseases and oncology. At Novartis, Suchismita served as a Medical Science Liaison and contributed to the launch of groundbreaking treatments for Multiple Sclerosis. Earlier roles included research associate and fellow positions at Calcutta University and the Calcutta School of Tropical Medicine, where Suchismita investigated nanotechnology applications and hematological disorders. Suchismita earned a Master's degree in Medical Biotechnology from The West Bengal University of Health Sciences and a Bachelor's degree in Biotechnology from Maulana Abul Kalam Azad University of Technology.